Diabetes, bone, pain drugs may face German price cuts

[riky]

Diabetes, bone, pain drugs may face German price cuts

FRANKFURT (Reuters) - Drugs from Novo Nordisk, Amgen, Bayer and other companies could face price cuts in Germany as the country's medical cost-benefit agency widens a review into the value offered by medicines. The Federal Joint Committee, or G-BA, said on Thursday it would review the cost-effectiveness of a range of drugs in different treatment areas. The list includes Novo's diabetes drug Victoza, Bayer's blood-thinner Xarelto, Amgen's osteoporosis medicine Prolia, Johnson & Johnson's painkiller Nucynta and Roche's rheumatoid arthritis drug Actemra. ...

Source: You are not allowed to view links. Register or Login